Physician profile
William Robinson
NPI 1811166705
$616.72
in general payments reported to CMS, 2019-2025
15 companies · $533 in 2025
The $533 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.89 · 2023: $37.38 · 2024: $17.83 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $109.34 | 2024-2025 | |
| Lilly USA, LLC | $95.04 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $81.48 | 2025 | Farxiga, Airsupra |
| Pfizer INC. | $68.59 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.88 | 2025 | Caplyta |
| Astellas Pharma US INC | $39.76 | 2025 | Veozah |
| Exact Sciences Corporation | $33.55 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $29.73 | 2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $21.50 | 2025 | |
| Glaxosmithkline, LLC. | $17.62 | 2025 | Trelegy Ellipta |
| Novo Nordisk INC | $16.66 | 2025 | Ozempic, Rybelsus |
| Amgen INC. | $16.43 | 2025 | Evenity, Prolia |
| Allergan, INC. | $15.30 | 2020 | |
| Dynavax Technologies Corporation | $15.25 | 2023 | Heplisav-B |
| Genentech USA, INC. | $13.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.